Malignant tumor
Conditions
Interventions
Dendritic cell vaccine therapy pulsed with neoantigen peptides.
Sponsors
KOUSHIKAI,Non-profitmedicalcorporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: A patient MUST: 1)Be diagnosed with malignant tumor by imaging findings or pathological or cytological study. 2)Have a successful genetic analysis of tumor sample at Seta Clinic Group. 3)Have an Eastern Cooperative Oncology Group performance-status score of 0 or 1. 4)Be 20 years of age or older. 5)Visit outpatient department on schedule. 6)Have an adequate function of liver, kidney, and bone marrow when the eligibility is confirmed. 7)Provide written consent to participate this study.
Exclusion criteria
Exclusion criteria: A patient MUST NOT: 1)Be apparent from the clinical manifestation of pulmonary fibrosis or interstitial pneumonia. 2)Have a history of a serious drug allergy. 3)Have a positive result of HIV antibody. 4)Have a serious cardiac disorder. 5)Have an active autoimmune disorder. 6)Have a concurrent cancer. 7)Have an infectious disorder that is difficult to control. 8)Be a female who is pregnant, lactating, or with a possibility of pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy | — |
Countries
Japan
Contacts
Public ContactEri Oguma
KOUSHIKAI,Non-profitmedicalcorporation Center for Clinical Trials and Research
Outcome results
None listed